Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,401–1,500 of 2,039
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Self-citationSong, S., Hyeon, M., Kim, S., Kang, Y., Hahm, S., Park, E. W., Shin, B. S., & Shin, S. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00540-5 · Cited by 1
Schlaich, M. P., Abhayaratna, W. P., Audehm, R. G., Ekinci, E. I., MacIsaac, R. J., Nelson, A. J., Sharma, A., & Pollock, C. (2026) · Internal Medicine Journal · doi:10.1111/imj.70403 · Cited by 1
Brunel, F. M., Parlee, S. D., Li, P., Lu, W., Chabenne, J. R., Pérez–Tilve, D., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00820 · Cited by 2
Farouk, H. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00609-y · Cited by 3
Caponio, D., & Acucella, G. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100696 · Cited by 2
Katsura, M., Horiuchi, Y., Tanabe, K., & Wettersten, N. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70721 · Cited by 1
“Mechanisms underlying this early and greater event reduction may involve tirzepatide's potent, rapid-onset anti-inflammatory effects beyond weight reduction, as suggested by prior studies [16, 17].”
Benny, O., Agarwal, A., Alecock, H., Subramani, R. G., Pawar, A., Shams, Z., Kermansaravi, M., Pouwels, S., Yang, W., Gerald, C., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.03.021 · Cited by 6
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
“42,43 It 44–46 In addition to this, there are new agents in the pipeline, such as once-monthly maridebart cafraglutide (MariTide) that may result in a more durable weight loss; data are awaited with interest.”
Zhou, X., Du, H., Wang, C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083448 · Cited by 1
Shao, H., Wu, Y., Mao, M., XiaoKe, N., Zhang, C., Chen, M., Guo, Z., Luo, J., Su, X., Wang, B., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03408 · Cited by 1
Adamidis, N., Margariti, T., Georgakopoulou, V., Adamidi, S., Desalermos, A. P., Kyventidou, M., Koutrakos, T., Bouros, D. E., Papadopoulou, N., & Adamidis, S. (2026) · Cureus · doi:10.7759/cureus.107081 · Cited by 3
Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists
Xue, C. (2026) · iNew Medicine · doi:10.1002/inm3.70048 · Cited by 2
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
“76 In non-diabetic overweight and obese populations, tirzepatide induced marked, dose-dependent weight loss (15–21% at 72 weeks) and reduced pro - gression to type 2 diabetes on long-term follow-up.”
Patel, D. (2026) · Cureus · doi:10.7759/cureus.107202 · Cited by 2
“Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 agonist administered by injection, achieved very large weight reductions in the SURMOUNT phase 3 obesity trial program [34] and strong glycemic control in SURPASS trials [35], often exceeding single-agonist GLP-1RAs.”
Li, J., Liang, J., Zhang, W., He, J., & Ye, X. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01872-6 · Cited by 5
Eisa, N., & Barood, O. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.04.014 · Cited by 2
Tirzepatide-associated interstitial kidney injury
Eldib, M., Mendpara, V. A., Herlitz, L., Álvarez, P. R., Dhingra, J. S., & Khan, L. Z. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag125 · Cited by 2
“Clinical studies, including a recent publication have demonstrated substantial HbA1c and body weight reductions, however, gastrointestinal adverse events are common and occur in approximately 10% of patients [22].”
Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study
Angelopoulos, N., Rizoulis, A. A., Boniakos, A., Fousteris, E., Mentzelopoulou, V., Zianni, D., Livadas, S., & Paparodis, R. D. (2026) · Nutrition · doi:10.1016/j.nut.2026.113286 · Cited by 4
Synthesis of scarless circular RNAs expressing long-acting GLP-1RAs for type 2 diabetes therapy
Lin, Y., Huang, Z., Xiao, Z., Wang, S., Liu, J. S., Chen, T., Zhang, W., Gu, S., Zhou, R., Yao, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.05.028 · Cited by 1
Pan, S., Weng, C., Sheen, Y., Chen, J., Lin, H., Wang, I., & Chou, C.-C. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101245 · Cited by 2
“3 These findings highlight tirzepatide’s potential to surpass GLP-1RAs not only in glycemic control but also in weight reduction, which are 2 factors intricately linked to the pathophysiology of glaucoma.”
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
“Comparative studies demonstrated superiority of tirzepatide in HbA1c and weight reductions compared with semaglutide 1.0 mg (SURPASS 2) and insulin deglu-dec (SURPASS 3) [105, 106].”
InfluentialTakahashi, N., Ohara, M., YOKOYAMA, H., Seino, H., Hiromura, M., Ozawa, S., Omachi, T., Takehana, N., Fujikawa, T., Ôhara, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01877-1 · Cited by 2
“…that tirzepatide treatment resulted in significantly greater reductions in glycated hemoglobin (HbA1c) and body weight compared to sema‑ glutide, an alternative weekly injectable GLP‑ 1RA, in patients with T2DM whose disease was inadequately controlled with metformin mono‑ therapy [10].”
Russo, M. F., Casella, G., Angelini, G., Russo, S. L. M. L., Casella-Mariolo, J. R., D'Andrea, V., Illuminati, G., & Castagneto‐Gissey, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70912 · Cited by 1
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70894 · Cited by 1
Vergniory-Trueba, O., & Lobato, C. T. (2026) · Obesities · doi:10.3390/obesities6030036 · Cited by 1
Incretin-based therapies: a new era in metabolic liver disease management
Elangovan, S., Cheah, C. C. M., & Goh, G. B. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.15 · Cited by 1
On the Noninferiority of Tirzepatide
Kaul, S. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.085 · Cited by 1
Piraccini, B. M., Vaño-Galvan, S., Blume‐Peytavi, U., Ribet, V., & Mengeaud, V. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01792-0 · Cited by 2
“[32–36].”
Kakkar, A. K., Payra, S., & Charaya, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70952 · Cited by 1
Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro)
Bhandari, P., Ray, A., Bhatt, P. R., Sapkota, S., Pande, S. K., Mustarin, S., Guragai, N., & Aziz, K. (2026) · Cureus · doi:10.7759/cureus.110692 · Cited by 1
Sacks, G. I., Meydan, Y., Lebens, R. S., & Mushlin, H. M. (2026) · European Spine Journal · doi:10.1007/s00586-026-10099-9 · Cited by 2
Gómez-Martín, Á., Marqués, P., Recatalá, C. A., Vea, À., Domingo, E., Alabadí, B., Real, J. T., Sanz, M., & Piqueras, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108321 · Cited by 2
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 4
“188 In the future, GLP-1R agonists may bene fi t all patients with metabolic cardiovascular risk by slowing the progression of cardiac remodeling, thereby reducing cardiovascular risk.”
Kahkedjian, F., Shah, J., & Kreidieh, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1885961 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“Tirzepatide more effectively improves glycemic control, leading to greater weight loss and fewer hypoglycemic episodes of 11–12 kg, surpassing dulaglutide results [243].”
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
Corso, H., Graybeal, A. J., Hoelscher, E., Roberson, S., Curran, B., Johnson, C., & Johnson, K. E. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1834580 · Cited by 3
Alsaleh, N. A., Seif‐Eldein, N. A., Malky, A. M. E., Al-Hashem, H., & Idriss, H. K. (2026) · World Journal of Surgery · doi:10.1002/wjs.70487 · Cited by 1
Wu, J., Lee, K.-W., Kao, C., Hung, K.-C., Yu, T., & Lin, Y. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047018 · Cited by 1
Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review
Alawad, A. O., Merghani, T. H., Fadelelmoula, T. E. Y., Elamin, N. A., Satti, S., Edris, A., Hakim, A., El-Hindi, R. F., Alhaj-Ali, A. A., Ibrahim, W. E., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261469947 · Cited by 1
“9,10,13 Beyond glycemic control, TZP has shown promising cardiometabolic benefits, including improvements in lipid profiles, blood pressure, and reductions in visceral adiposity.”
InfluentialAl-Rashid, A. H., & Ali, F. (2026) · Cureus · doi:10.7759/cureus.113910 · Cited by 1
Amylin: A Multi‐Functional Pancreatic Hormone—A Review
Foll, C. L., & Lutz, T. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71146 · Cited by 1
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study
Krüger, N., Schneeweiß, S., & Wang, S. V. (2026) · BMJ · doi:10.1136/bmj-2026-100011 · Cited by 2
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
Takiyama, T., Kitsunai, H., Maruyama, F., Kitao, N., Wakabayashi, Y., Ito, M., Kurihara, H., Yamamoto, K., Takeuchi, J., Nanbu, T., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109391 · Cited by 1
Green, D., & Glynn, N. (2026) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-26-0059 · Cited by 1
Presentations at the 81st scientific sessions of the American Diabetes Association , part 2
Bloomgarden, Z. T. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13219 · Cited by 1
Vidal, J. P. (1986) · Memoria digital de Canarias (Universidad de Las Palmas de Gran Canaria) · Cited by 3
Selección de lo mejor del año en 2022 en riesgo vascular y rehabilitación cardiaca
Olmo, M. R. F., Fort, A. C., Llergo, J. T., Martín, D. M., Alonso, M. B., Quesada, M. M., Palau, P., & Ruíz, R. C. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2022.10.002 · Cited by 1
Drugs used in the management of hyperglycaemia
Lynch, E., & Llano, A. (2022) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2022.10.014 · Cited by 1
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Talha, K. M., Fonarow, G. C., Virani, S. S., & Butler, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1155 · Cited by 1
Lowy, L., & Kasianchuk, A. (2023) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000848 · Cited by 2
Mazaheri, T., Ansari, S., Nallagonda, M., Kollmann, L., Nickel, F., Seyfried, F., & Miras, A. D. (2023) · Die Chirurgie · doi:10.1007/s00104-023-01830-z · Cited by 3
Elrggal, M. E., Elkeraie, A. F., Carriazo, S. M., Sawaf, H., Khor, S. Y., Elkeraie, Y., Haddad, I. R., Moustafa, K., & Hassanein, M. M. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070009 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
STACHYRA, B., WOLANIN, M., STAWIKOWSKI, C., ZIELONKA, B., Osińska, A., WOLANIN, I., MADEJ, K., Dengler, B., KOWALCZYK, I., & KRAWIEC, P. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.18.01.003 · Cited by 2
Analysis of a Binary Outcome Dichotomized from an Underlying Continuous Variable in Clinical Trials
Li, J., Du, Y., & Qu, Y. (2023) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-023-00538-w · Cited by 1
“, 10%) are often important endpoints [3].”
Tirzepatide for the treatment of adults with type 2 diabetes
Chaplin, S. (2023) · Prescriber · doi:10.1002/psb.2081 · Cited by 2
Terapi Diabetes Melitus Tipe 2 Berbasis Hormon Inkretin
Antoni, M. (2023) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v29i2.2664 · Cited by 8
Thompson, T., Rahman, H., Sprando, A., & Friedlander, M. P. (2023) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001948 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Kurt, B., & Kahles, F. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01109-1 · Cited by 1
Type 2 Diabetes and Pre-Diabetes in Pediatric Obesity
Bensignor, M. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_9 · Cited by 1
Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual
Olmo, M. R. F., & Llergo, J. T. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00011-0 · Cited by 2
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Al‐Omar, H. A., Almodaimegh, H., Omaer, A., Alzubaidi, L. M. Y., Al-Harbi, B., Al-Harbi, I., Hassan, M., & Akhtar, O. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2319458 · Cited by 2
New Antidiabetic Agents for the Treatment of Heart Failure in Hypertensive Patients
Nilsson, P. M., Holm, H., & Magnusson, M. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_23 · Cited by 1
Insulin Delivery Hardware: Pumps and Pens
Lal, R., & Leelarathna, L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2503 · Cited by 1
“The treatment of T2D has changed over the years with the introduction of novel GLP-1 and dual agonists and SGLT-2 inhibitors (14,15).”
Tirzepatid - der Gamechanger in der Diabetestherapie?
Negrean, M. (2024) · Info Diabetologie · doi:10.1007/s15034-023-4901-y · Cited by 1
Pharmakotherapie der Adipositas
Roser, P. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01167-z · Cited by 1
Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
Keedy, C. A., & Bland, C. M. (2024) · JAAPA · doi:10.1097/01.jaa.0000000000000017 · Cited by 1
Varadhan, L., Jose, M., Humphreys, T., et al. (2024) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715241257970 · Cited by 1
Raval, H., & Sangave, P. C. (2024) · Current Nanomedicine · doi:10.2174/0124681873309964240521074809 · Cited by 3
Second Generation Anti-Obesity Medications
Chimatapu, S. N., Mittelman, S. D., & Singhal, V. (2024) · Current Pediatrics Reports · doi:10.1007/s40124-024-00326-6 · Cited by 2
Yousif, A. B., Mudarres, M. F., Yousef, M. F., Badawi, A., & Hassan, E. A. (2024) · Yemen Journal of Medicine · doi:10.18231/j.yjom.2024.005 · Cited by 2
“12 In separate trials, SURMOUNT-1 documented 16–22.5% weight loss over 72 weeks in non-diabetic individuals, contrasting with a 2.4% weight loss in the placebo group.”
InfluentialFeldman-Billard, S. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.4521 · Cited by 1
Zhang, K., Zhao, A., Wang, Z., Ye, K., Xu, Z., Gong, X., & Zhu, G. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01449-1 · Cited by 1
New class of drugs for the treatment of diabetes mellitus
Islamova, A. I., Sabirova, A. R., Batyrshina, E. R., Muzafarova, G. N., Khabibullina, L. H., Kiraeva, A. E., Pyatyshina, A. V., Arslanova, E., Vinnikova, A. A., Pisarev, A. A., et al. (2024) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2024-102-7-499-509 · Cited by 1
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0389 · Cited by 1
“Neuerung 1: Aktualisierung Abschnitt GLP-1-Rezeptor-Ago-nisten und -Koagonisten Begründung: Neue Studiendaten Stützende Quellenangabe: [27] Neuerung 2: Hinzunahme von E-health Begründung: Neue Studiendaten und Leitlinien Gewichtsreduktion ist ein integraler Bestandteil in der Therapie vieler…”
Kamrul-Hasan, A. B. M., Selim, S., Afsana, F., Nagendra, L., Ahmed, R., & Dutta, D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.12.005 · Cited by 2
Ojaimi, R. E., Cheisson, G., Cosson, E., Ichaï, C., Jacqueminet, S., Catargi, B., Ouattara, A., Tauveron, I., Valensi, P. E., & Benhamou, D. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101468 · Cited by 1
Differences in GIP Receptor Expression by Feeding Status in the Mouse Brain
Song, D. K., Jung, N., Sung, Y., Hong, Y. S., & Lee, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031142 · Cited by 1
Yu, H., Feng, N., Zhong, W., Han, Y., Cheng, Y., Zhang, Z., Wang, Y., Gao, P., Huang, R., Zhang, C., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202402546r · Cited by 2
“25,26 29 Recently, it has been reported that local actions of the gut peptide GLP-1 are sufficient to cause marked appetite suppression including the activation of NTS. 30 The activated neurons in NTS project to the ventral tegmental area, the nucleus accumbens, and the hypothalamus and…”
Gartner, H. T., Simmons, R. E., Wan, H. Z., Sollee, D. R., & Sheikh, S. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251334642 · Cited by 1
Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview
Davies, C. (2025) · Nursing Standard · doi:10.7748/ns.2025.e12464 · Cited by 1
Xie, S., Ye, L., Yang, A., Li, X., & Yin, Y. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2618-7509 · Cited by 2
“Re - search indicates that therapies which maintain or elevate C-Pep - tide levels can profoundly impact the clinical course of diabetes by potentially delaying or preventing the onset of diabetes-related complications such as nephropathy, retinopathy, and neuropathy [11–13].”
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
Mews, K., & Momchilovich, D. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0074 · Cited by 1
Diabetes mellitus: An overview
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00007-x · Cited by 1
Twinkretin überzeugt bei Typ-2-Diabetes
Pampel, S. L. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3734-9 · Cited by 1
Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?
Paneni, F., & Patrono, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab636 · Cited by 3
Doubles-agonistes, tri-agonistes et multi-agonistes incrétines/glucagon
Phan, F., & Andréelli, F. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.010 · Cited by 3
Médicaments anti-obésité : leçons des échecs pour l’avenir
Scheen, A. J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.012 · Cited by 4
Modarressi, T. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88c.12001 · Cited by 1
Ausblick auf neue Arzneimittel zur Gewichtsreduktion
Engeli, S. (2022) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1722-5945 · Cited by 1
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.